This group comprises preparations used in the treatment of malignant neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.
Immunosuppressants, see L04A.
Levamisole, which also affects the immune response, is classified in P02CE.
L03AX Other immunostimulants
The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).
Last updated: 2013-12-19